These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 33245746

  • 1. Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme.
    Winthrop KL, Loftus EV, Baumgart DC, Reinisch W, Nduaka CI, Lawendy N, Chan G, Mundayat R, Friedman GS, Salese L, Thorpe AJ, Su C.
    J Crohns Colitis; 2021 Jun 22; 15(6):914-929. PubMed ID: 33245746
    [Abstract] [Full Text] [Related]

  • 2. Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
    Winthrop KL, Vermeire S, Long MD, Panés J, Ng SC, Kulisek N, Mundayat R, Lawendy N, Vranic I, Modesto I, Su C, Melmed GY.
    Inflamm Bowel Dis; 2023 Jan 05; 29(1):85-96. PubMed ID: 35648151
    [Abstract] [Full Text] [Related]

  • 3. Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure.
    Panés J, D'Haens GR, Sands BE, Ng SC, Lawendy N, Kulisek N, Guo X, Wu J, Vranic I, Panaccione R, Vermeire S.
    United European Gastroenterol J; 2024 Jul 05; 12(6):793-801. PubMed ID: 38778549
    [Abstract] [Full Text] [Related]

  • 4. Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials.
    Sandborn WJ, Panés J, D'Haens GR, Sands BE, Su C, Moscariello M, Jones T, Pedersen R, Friedman GS, Lawendy N, Chan G.
    Clin Gastroenterol Hepatol; 2019 Jul 05; 17(8):1541-1550. PubMed ID: 30476584
    [Abstract] [Full Text] [Related]

  • 5. Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme.
    Sandborn WJ, D'Haens GR, Sands BE, Panaccione R, Ng SC, Lawendy N, Kulisek N, Modesto I, Guo X, Mundayat R, Su C, Vranic I, Panés J.
    J Crohns Colitis; 2023 Apr 03; 17(3):338-351. PubMed ID: 36124702
    [Abstract] [Full Text] [Related]

  • 6. Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
    Winthrop KL, Melmed GY, Vermeire S, Long MD, Chan G, Pedersen RD, Lawendy N, Thorpe AJ, Nduaka CI, Su C.
    Inflamm Bowel Dis; 2018 Sep 15; 24(10):2258-2265. PubMed ID: 29850873
    [Abstract] [Full Text] [Related]

  • 7. Clostridium difficile Infection in Patients with Ulcerative Colitis Treated with Tofacitinib in the Ulcerative Colitis Program.
    Loftus EV, Baumgart DC, Gecse K, Kinnucan JA, Connelly SB, Salese L, Su C, Kwok KK, Woolcott JC, Armuzzi A.
    Inflamm Bowel Dis; 2023 May 02; 29(5):744-751. PubMed ID: 35792493
    [Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of long-term tofacitinib treatment in East Asian patients with ulcerative colitis in OCTAVE Open.
    Matsuoka K, Hisamatsu T, Kim HJ, Ye BD, Arai S, Hoshi M, Yuasa H, Tabira J, Toyoizumi S, Shi N, Woo JS, Hibi T.
    J Gastroenterol Hepatol; 2022 Oct 02; 37(10):1884-1892. PubMed ID: 35734858
    [Abstract] [Full Text] [Related]

  • 9. Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program.
    Lichtenstein GR, Rogler G, Ciorba MA, Su C, Chan G, Pedersen RD, Lawendy N, Quirk D, Nduaka CI, Thorpe AJ, Panés J.
    Inflamm Bowel Dis; 2021 May 17; 27(6):816-825. PubMed ID: 32766762
    [Abstract] [Full Text] [Related]

  • 10. Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.
    Panés J, Vermeire S, Lindsay JO, Sands BE, Su C, Friedman G, Zhang H, Yarlas A, Bayliss M, Maher S, Cappelleri JC, Bushmakin AG, Rubin DT.
    J Crohns Colitis; 2018 Jan 24; 12(2):145-156. PubMed ID: 29028981
    [Abstract] [Full Text] [Related]

  • 11. Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program.
    Lichtenstein GR, Bressler B, Francisconi C, Vermeire S, Lawendy N, Salese L, Sawyerr G, Shi H, Su C, Judd DT, Jones T, Loftus EV.
    Inflamm Bowel Dis; 2023 Jan 05; 29(1):27-41. PubMed ID: 36342120
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status.
    Sandborn WJ, Peyrin-Biroulet L, Sharara AI, Su C, Modesto I, Mundayat R, Gunay LM, Salese L, Sands BE.
    Clin Gastroenterol Hepatol; 2022 Mar 05; 20(3):591-601.e8. PubMed ID: 33684552
    [Abstract] [Full Text] [Related]

  • 13. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
    Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Panés J, OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators.
    N Engl J Med; 2017 May 04; 376(18):1723-1736. PubMed ID: 28467869
    [Abstract] [Full Text] [Related]

  • 14. Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Infection Rates in Ulcerative Colitis.
    Lichtenstein GR, Cohen BL, Salese L, Modesto I, Wang W, Chan G, Ahmed HM, Su C, Peyrin-Biroulet L.
    Dig Dis Sci; 2023 Jun 04; 68(6):2624-2634. PubMed ID: 36739367
    [Abstract] [Full Text] [Related]

  • 15. Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical Program.
    Sands BE, Long MD, Reinisch W, Panés J, Loftus EV, Nduaka CI, Soonasra A, Mundayat R, Lawendy N, Chan G, Friedman GS, Su C.
    Inflamm Bowel Dis; 2022 Feb 01; 28(2):234-245. PubMed ID: 33742652
    [Abstract] [Full Text] [Related]

  • 16. Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study.
    Calabrese LH, Abud-Mendoza C, Lindsey SM, Lee SH, Tatulych S, Takiya L, Iikuni N, Soma K, Luo Z, Fleischmann R.
    Arthritis Care Res (Hoboken); 2020 Mar 01; 72(3):353-359. PubMed ID: 31207152
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open.
    Sands BE, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, Panés J, Bressler B, Colombel JF, Lawendy N, Maller E, Zhang H, Chan G, Salese L, Tsilkos K, Marren A, Su C.
    Aliment Pharmacol Ther; 2020 Jan 01; 51(2):271-280. PubMed ID: 31660640
    [Abstract] [Full Text] [Related]

  • 18. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.
    Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Thirunavukkarasu K, DeMasi R, Geier J, Kwok K, Wang L, Riese R, Wollenhaupt J.
    Ann Rheum Dis; 2017 Jul 01; 76(7):1253-1262. PubMed ID: 28143815
    [Abstract] [Full Text] [Related]

  • 19. Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial.
    Mukherjee A, Hazra A, Smith MK, Martin SW, Mould DR, Su C, Niezychowski W.
    Br J Clin Pharmacol; 2018 Jun 01; 84(6):1136-1145. PubMed ID: 29377257
    [Abstract] [Full Text] [Related]

  • 20. Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis.
    Sands BE, Taub PR, Armuzzi A, Friedman GS, Moscariello M, Lawendy N, Pedersen RD, Chan G, Nduaka CI, Quirk D, Salese L, Su C, Feagan BG.
    Clin Gastroenterol Hepatol; 2020 Jan 01; 18(1):123-132.e3. PubMed ID: 31077827
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.